Literature DB >> 21445925

Decellularized liver matrix as a carrier for the transplantation of human fetal and primary hepatocytes in mice.

Ping Zhou1, Nataly Lessa, Daniel C Estrada, Ella B Severson, Shilpa Lingala, Mark A Zern, Jan A Nolta, Jian Wu.   

Abstract

The transplantation of primary hepatocytes has been shown to augment the function of damaged livers and to bridge patients to liver transplantation. However, primary hepatocytes often have low levels of engraftment and survive for only a short time after transplantation. To explore the potential benefits of using decellularized liver matrix (DLM) as a carrier for hepatocyte transplantation, DLM from whole mouse livers was generated. Human fetal hepatocytes immortalized by telomerase reconstitution (FH-hTERTs) or primary human hepatocytes were infused into the DLM, which was then implanted into the omenta of immunodeficient nonobese diabetic/severe combined immunodeficient/interleukin-2 receptor γ-deficient mice or nonobese diabetic/severe combined immunodeficient/mucopolysaccharidosis type VII mice. The removal of endogenous cellular components and the preservation of the extracellular matrix proteins and vasculature were demonstrated in the resulting DLM. Bioluminescent imaging revealed that FH-hTERTs transduced with a lentiviral vector expressing firefly luciferase survived in the DLM for 8 weeks after peritoneal implantation, whereas the luciferase signal from FH-hTERTs rapidly declined in control mice 3 to 4 weeks after transplantation via splenic injection or omental implantation after Matrigel encapsulation. Furthermore, primary human hepatocytes that were reconstituted in the DLM not only survived 6 weeks after transplantation but also maintained their function, as demonstrated by messenger RNA levels of albumin and cytochrome P450 (CYP) subtypes (CYP3A4, CYP2C9, and CYP1A1) similar to the levels in freshly isolated human primary hepatocytes (hPHs). In contrast, when hPHs were transplanted into mice via splenic injection, they failed to express CYP3A4, although they expressed albumin. In conclusion, DLM provides an excellent environment for long-term survival and maintenance of the hepatocyte phenotype after transplantation.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21445925      PMCID: PMC3079538          DOI: 10.1002/lt.22270

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  32 in total

1.  Assessing porcine liver-derived biomatrix for hepatic tissue engineering.

Authors:  Paul Lin; Warren C W Chan; Stephen F Badylak; Sangeeta N Bhatia
Journal:  Tissue Eng       Date:  2004 Jul-Aug

2.  Acellular liver matrix improves the survival and functions of isolated rat hepatocytes cultured in vitro.

Authors:  Patrizia Burra; Silvia Tomat; Maria Teresa Conconi; Carlo Macchi; Francesco P Russo; Pier Paolo Parnigotto; Remo Naccarato; Gastone G Nussdorfer
Journal:  Int J Mol Med       Date:  2004-10       Impact factor: 4.101

3.  Simplified mammalian DNA isolation procedure.

Authors:  P W Laird; A Zijderveld; K Linders; M A Rudnicki; R Jaenisch; A Berns
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

4.  Engineered liver-like tissue on a capillarized matrix for applied research.

Authors:  Kirstin Linke; Johanna Schanz; Jan Hansmann; Thorsten Walles; Herwig Brunner; Heike Mertsching
Journal:  Tissue Eng       Date:  2007-11

5.  Biological vascularized matrix for bladder tissue engineering: matrix preparation, reseeding technique and short-term implantation in a porcine model.

Authors:  Dirk Schultheiss; Alexander I Gabouev; Serghei Cebotari; Igor Tudorache; Thorsten Walles; Norbert Schlote; Jörg Wefer; P Matthias Kaufmann; Axel Haverich; Udo Jonas; Christian G Stief; Heike Mertsching
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

6.  Integrin and extracellular matrix interactions regulate engraftment of transplanted hepatocytes in the rat liver.

Authors:  Vinay Kumaran; Brigid Joseph; Daniel Benten; Sanjeev Gupta
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

7.  The use of human hepatocyte cultures to study the induction of cytochrome P-450.

Authors:  V E Kostrubsky; V Ramachandran; R Venkataramanan; K Dorko; J E Esplen; S Zhang; J F Sinclair; S A Wrighton; S C Strom
Journal:  Drug Metab Dispos       Date:  1999-08       Impact factor: 3.922

8.  Human cord blood progenitors with high aldehyde dehydrogenase activity improve vascular density in a model of acute myocardial infarction.

Authors:  Claus S Sondergaard; David A Hess; Dustin J Maxwell; Carla Weinheimer; Ivana Rosová; Michael H Creer; David Piwnica-Worms; Attila Kovacs; Lene Pedersen; Jan A Nolta
Journal:  J Transl Med       Date:  2010-03-09       Impact factor: 5.531

9.  Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease.

Authors:  A Alex Hofling; Steven Devine; Carole Vogler; Mark S Sands
Journal:  Mol Ther       Date:  2004-06       Impact factor: 11.454

10.  Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells.

Authors:  Ivana Rosová; Mo Dao; Ben Capoccia; Daniel Link; Jan A Nolta
Journal:  Stem Cells       Date:  2008-05-29       Impact factor: 6.277

View more
  26 in total

Review 1.  Liver-Regenerative Transplantation: Regrow and Reset.

Authors:  A Collin de l'Hortet; K Takeishi; J Guzman-Lepe; K Handa; K Matsubara; K Fukumitsu; K Dorko; S C Presnell; H Yagi; A Soto-Gutierrez
Journal:  Am J Transplant       Date:  2016-02-18       Impact factor: 8.086

2.  Advancements in in vitro hepatic models: application for drug screening and therapeutics.

Authors:  Apeksha Damania; Era Jain; Ashok Kumar
Journal:  Hepatol Int       Date:  2013-12-05       Impact factor: 6.047

3.  Decellularized liver scaffolds effectively support the proliferation and differentiation of mouse fetal hepatic progenitors.

Authors:  Xiaojun Wang; Jing Cui; Bing-Qiang Zhang; Hongyu Zhang; Yang Bi; Quan Kang; Ning Wang; Ping Bie; Zhanyu Yang; Huaizhi Wang; Xiangde Liu; Rex C Haydon; Hue H Luu; Ni Tang; Jiahong Dong; Tong-Chuan He
Journal:  J Biomed Mater Res A       Date:  2013-06-04       Impact factor: 4.396

4.  Mesenchymal stem cells support hepatocyte function in engineered liver grafts.

Authors:  Yoshie Kadota; Hiroshi Yagi; Kenta Inomata; Kentaro Matsubara; Taizo Hibi; Yuta Abe; Minoru Kitago; Masahiro Shinoda; Hideaki Obara; Osamu Itano; Yuko Kitagawa
Journal:  Organogenesis       Date:  2014-01-31       Impact factor: 2.500

Review 5.  Decellularization and cell seeding of whole liver biologic scaffolds composed of extracellular matrix.

Authors:  Denver M Faulk; Justin D Wildemann; Stephen F Badylak
Journal:  J Clin Exp Hepatol       Date:  2014-03-28

6.  Decellularized spleen matrix for reengineering functional hepatic-like tissue based on bone marrow mesenchymal stem cells.

Authors:  Junxi Xiang; Xinglong Zheng; Peng Liu; Lifei Yang; Dinghui Dong; Wanquan Wu; Xuemin Liu; Jianhui Li; Yi Lv
Journal:  Organogenesis       Date:  2016-05-09       Impact factor: 2.500

Review 7.  Engineered liver for transplantation.

Authors:  Basak E Uygun; Martin L Yarmush
Journal:  Curr Opin Biotechnol       Date:  2013-06-20       Impact factor: 9.740

Review 8.  Application of whole-organ tissue engineering in hepatology.

Authors:  Basak E Uygun; Martin L Yarmush; Korkut Uygun
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-08-14       Impact factor: 46.802

Review 9.  Immunogenicity in xenogeneic scaffold generation: antigen removal vs. decellularization.

Authors:  Maelene L Wong; Leigh G Griffiths
Journal:  Acta Biomater       Date:  2014-01-31       Impact factor: 8.947

10.  ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.

Authors:  Alejandro E Mayorca-Guiliani; Chris D Madsen; Thomas R Cox; Edward R Horton; Freja A Venning; Janine T Erler
Journal:  Nat Med       Date:  2017-06-12       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.